Detalles de la búsqueda
1.
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Br J Cancer
; 119(11): 1401-1409, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30353044
2.
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Gynecol Oncol
; 140(2): 199-203, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26723501
3.
Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.
Clin Colorectal Cancer
; 8(1): 59-60, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19203899
4.
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
Oncotarget
; 8(27): 43653-43661, 2017 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28525389
5.
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
Clin Cancer Res
; 23(15): 4086-4094, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28223274
6.
KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Eur J Cancer
; 49(10): 2424-32, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23510802
7.
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
J Clin Oncol
; 30(29): 3596-603, 2012 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-22965965
8.
An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.
Leuk Res
; 34(2): 196-202, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19674789
Resultados
1 -
8
de 8
1
Próxima >
>>